Rachel Levinson-Castiel1, Rami Eliakim2,3, Eilat Shinar4, Tsachi-Tsadok Perets3,5, Olga Layfer5, Nina Levhar2,3, Michael Schvimer6, Luba Marderfeld1,7, Shomron Ben-Horin2,3, Raanan Shamir1,3. 1. Schneider Children's Medical Center, Institute for Gastroenterology, Nutrition and Liver Diseases, Petach Tikva, Israel. 2. Department of Gastroenterology, Sheba Medical Center, Ramat Gan, Israel. 3. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 4. Magen David Adom, National Blood Services, Ramat Gan, Israel. 5. Gastroenterology Laboratory, Rabin Medical Center, Petach Tikva, Israel. 6. Institute of Pathology, Sheba Medical Center, Ramat Gan, Israel. 7. Nutrition and Dietetics Department, Schneider Children's Medical Center, Petach Tikva, Israel.
Abstract
Background: Recent studies suggest that the prevalence of celiac disease is rising. We previously established the prevalence of celiac disease in healthy blood donors in 2002. Objective: The purpose of this study was to examine whether the prevalence of celiac disease and celiac disease autoimmunity has changed over time by performing a similar prospective study. Methods: Healthy blood donors (n = 1908) were tested for tissue transglutaminase antibodies and for anti-endomysial antibodies when positive. Further evaluation followed accepted criteria for diagnosis. Results: Overall, 32 donors had abnormal tissue transglutaminase antibodies (1.68%). Eight donors had tissue transglutaminase antibodies >3 × upper limit of normal (0.42%), two of them with tissue transglutaminase antibodies >10 × upper limit of normal, while 24 donors had tissue transglutaminase antibodies <3 × upper limit of normal (1.26%). Most of the donors with positive tissue transglutaminase antibodies <3 × upper limit of normal had negative tissue transglutaminase antibodies levels on repeated testing (18/19). Celiac disease was diagnosed in four donors with positive tissue transglutaminase antibodies, establishing a prevalence of 1.68% (95% confidence interval 1.15-2.3) for celiac disease autoimmunity and 0.21% for celiac disease (95% confidence interval 0.07-0.5%). Conclusion: The prevalence of celiac disease in blood donors in Israel did not rise in the last 15 years, suggesting that the increased prevalence of diagnosed celiac disease is mainly due to increased awareness. As most of the donors with elevated tissue transglutaminase antibodies <3 × upper limit of normal were endomysial antibody negative and had a negative tissue transglutaminase antibodies result upon re-testing, repeated tissue transglutaminase antibodies testing is required when screening asymptomatic populations for celiac disease.
Background: Recent studies suggest that the prevalence of celiac disease is rising. We previously established the prevalence of celiac disease in healthy blood donors in 2002. Objective: The purpose of this study was to examine whether the prevalence of celiac disease and celiac disease autoimmunity has changed over time by performing a similar prospective study. Methods: Healthy blood donors (n = 1908) were tested for tissue transglutaminase antibodies and for anti-endomysial antibodies when positive. Further evaluation followed accepted criteria for diagnosis. Results: Overall, 32 donors had abnormal tissue transglutaminase antibodies (1.68%). Eight donors had tissue transglutaminase antibodies >3 × upper limit of normal (0.42%), two of them with tissue transglutaminase antibodies >10 × upper limit of normal, while 24 donors had tissue transglutaminase antibodies <3 × upper limit of normal (1.26%). Most of the donors with positive tissue transglutaminase antibodies <3 × upper limit of normal had negative tissue transglutaminase antibodies levels on repeated testing (18/19). Celiac disease was diagnosed in four donors with positive tissue transglutaminase antibodies, establishing a prevalence of 1.68% (95% confidence interval 1.15-2.3) for celiac disease autoimmunity and 0.21% for celiac disease (95% confidence interval 0.07-0.5%). Conclusion: The prevalence of celiac disease in blood donors in Israel did not rise in the last 15 years, suggesting that the increased prevalence of diagnosed celiac disease is mainly due to increased awareness. As most of the donors with elevated tissue transglutaminase antibodies <3 × upper limit of normal were endomysial antibody negative and had a negative tissue transglutaminase antibodies result upon re-testing, repeated tissue transglutaminase antibodies testing is required when screening asymptomatic populations for celiac disease.
Authors: Prashant Singh; Ananya Arora; Tor A Strand; Daniel A Leffler; Carlo Catassi; Peter H Green; Ciaran P Kelly; Vineet Ahuja; Govind K Makharia Journal: Clin Gastroenterol Hepatol Date: 2018-03-16 Impact factor: 11.382
Authors: Kaisa M Kemppainen; Kristian F Lynch; Edwin Liu; Maria Lönnrot; Ville Simell; Thomas Briese; Sibylle Koletzko; William Hagopian; Marian Rewers; Jin-Xiong She; Olli Simell; Jorma Toppari; Anette-G Ziegler; Beena Akolkar; Jeffrey P Krischer; Åke Lernmark; Heikki Hyöty; Eric W Triplett; Daniel Agardh Journal: Clin Gastroenterol Hepatol Date: 2016-11-10 Impact factor: 11.382
Authors: S Husby; S Koletzko; I R Korponay-Szabó; M L Mearin; A Phillips; R Shamir; R Troncone; K Giersiepen; D Branski; C Catassi; M Lelgeman; M Mäki; C Ribes-Koninckx; A Ventura; K P Zimmer Journal: J Pediatr Gastroenterol Nutr Date: 2012-01 Impact factor: 2.839
Authors: Ida Judyta Malesza; Michał Malesza; Iwona Krela-Kaźmierczak; Aleksandra Zielińska; Eliana B Souto; Agnieszka Dobrowolska; Piotr Eder Journal: Int J Mol Sci Date: 2020-07-23 Impact factor: 5.923